Proteon banks $61M in a down-sized IPO as it moves on without Novartis

Proteon Therapeutics ($PRTO) priced its IPO below its expected range, clearing $61 million to pay the way for its investigational vascular drug. The Massachusetts biotech moved 6.1 million shares at $10 each, a price that fell lower than its planned $12 to $14. The money will support the Phase III development of PRT-201, a synthetic enzyme that can help dilate arteries and veins. Earlier this year, Novartis ($NVS) walked away from its option to buy Proteon for up to $550 million, and now the biotech is carrying on with PRT-201 on its own, in May securing $45 million in venture commitments as it works through late-stage study. News

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.